Abeona Therapeutics price target lowered to $20 from $27.50 at Alliance Global

Alliance Global lowered the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $27.50 and keeps a Buy rating on the shares following FY25 results. Alliance Global told investors in a research note that the company’s earnings conference call focus included Zevaskyn’s early launch progression, particularly the scale-up of Abeona Therapeutics’ Qualified Treatment Center network to progress patient treatment. The firm noted that the price target cut accounts for its adjusted launch expectations of a more conservative launch trajectory.